Exagen
XGN
53 hedge funds and large institutions have $73M invested in Exagen in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 7 closing their positions.
2.78% more ownership
Funds ownership: 53.23% → 56.01% (+2.8%)
0% more funds holding
Funds holding: 53 → 53 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
27% less capital invested
Capital invested by funds: $100M → $73M (-$27M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.26M |
| 2 |
RI
RTW Investments
New York
|
+$1.45M |
| 3 |
CCPM
Cooper Creek Partners Management
New York
|
+$1.32M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$207K |
| 5 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
+$188K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$610K |
| 2 |
Millennium Management
New York
|
-$341K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$239K |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$142K |
| 5 |
Goldman Sachs
New York
|
-$125K |
XGN Hedge Fund Activity: Q1 2022 in Review
53 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q1 2022, worth a combined $73M — down 27% from $100M a quarter earlier.
Fund positioning in XGN was balanced in Q1 2022: 7 funds opened new positions, 7 closed out, 16 added to existing stakes and 20 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $2.26M. The largest seller was Maven Securities, exiting entirely with an estimated $610K sold.
- 53 institutional investors held Exagen (XGN) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $73M of Exagen stock for Q1 2022, down 27% quarter-over-quarter.
- 7 funds opened new Exagen positions in Q1 2022 and 7 closed out, a net change of 0 holders.
- The largest Exagen buyer in Q1 2022 was Stonepine Capital Management, an estimated $2.26M added.
- The largest Exagen seller in Q1 2022 was Maven Securities, an estimated $610K sold.
Based on aggregated 13F filings for Q1 2022.